Glycosmedia Weekly Diabetes News - 06/26/2020

Exenatide ER in patients with Type 1 diabetes with and without residual insulin production

Treatment with exenatide ER may have short‐term benefits in some individuals with T1D who are overweight or with detectable levels of C‐peptide, but short term improvements were not sustained (Diabetes, Obesity and Metabolism)

Treatment Options for MODY Patients: A Systematic Review of Literature

Our aim is to provide the reader with an easy-to-read update that can be used to drive the clinician’s therapeutical approach to these patients after the molecular diagnosis (Diabetes Therapy)

COVID-19 and Type 1 Diabetes: Challenges and actions

The authors of this commentary are involved in the care of T1D in LMICs and see services in such settings suffering in three major ways from the impacts of COVID-19 (Diabetes Research and Clinical Practice)

ABCD issues Recovery Guidance

A Quick guidance to Risk Stratification and recovery of Diabetes Services in the post – Covid-19 Era (ABCD)

The unique association between the level of peripheral blood monocytes and the prevalence of diabetic retinopathy: a cross-sectional study

Decreased peripheral blood monocyte levels were associated with increased odds of DR after adjusting for potential confounders in diabetic adults. However, causation remains to be demonstrated(Journal of Translational Medicine)

Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication

C-reactive protein may help to identify patients with diabetes who are at greater risk of dying during hospitalization. Older patients with diabetes were prone to death related to COVID-19. Attention needs to be paid to patients with diabetes and COVID-19 who use insulin. ACEI/ARB use showed no significant impact on patients with diabetes and hypertension who have COVID-19 (Diabetes Care)

Early Metabolic Features of Genetic Liability to Type 2 Diabetes: Cohort Study With Repeated Metabolomics Across Early Life

Our results support perturbed HDL lipid metabolism as one of the earliest features of type 2 diabetes liability, alongside higher branched-chain amino acid and inflammatory levels. Several features are apparent in childhood as early as age 8 years, decades before the clinical onset of disease (Diabetes Care)

Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update

Timely insulin initiation may prevent diabetes progression, reduce diabetes-related complications and has less serious adverse effects (Diabetes Therapy)

American Diabetes Association “Standards of Medical Care—2020 for Gestational Diabetes Mellitus”: A Critical Appraisal

This article provides a critical appraisal of the recently published ADA guidance document with regard to the diagnosis of GDM (Diabetes Therapy)

Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

This Consensus Report describes a foundation for precision diabetes medicine, while highlighting what remains to be done to realize its potential (Diabetes Care)

Pioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors

Pioglitazone use decreased the risk of new-onset ischemic stroke in Asian patients with type 2 DM and CV risk factors (Cardiovascular Diabetology)